Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Softline reported for 9 months of 2023 by RAS

11/7/23 SOFL

Vertex Pharmaceuticals reported for 9 months of 2023

11/7/23 VRTX

Aimco reported for 9 months of 2023

11/7/23 AIV

Alteryx reported for 9 months of 2023

11/7/23 AYX

Rosneft built a quarter of the pipeline for Vostok Oil

11/6/23 ROSN

SPB Exchange discusses sanctions with market participants

11/6/23 SPBE

SPB Exchange is not ready to resume trading in foreign securities

11/6/23 SPBE

Berkshire Hathaway reported for 9 months of 2023

11/6/23 BRK.B

Lenenergo reported for 9 months of 2023 by RAS

11/3/23 LSNG

Rosseti reported for 9 months of 2023 by RAS

11/3/23 FEES